HIGHLIGHTS
- who: Ethan Heh and collaborators from the Paul LFoster School of Medicine, Department of Medical Education, Texas Tech University Health Sciences Center, El Paso, TX, USA have published the paper: Peptide Drug Conjugates and Their Role in Cancer Therapy, in the Journal: (JOURNAL)
- what: The need for targeted cancer therapy is more significant than ever.
- how: The authors identified 44 clinical trials that employ Lu-177 as the payload for PDC cancer therapy.
- future: Similarly critical technical hurdles to the development of effective PDCs will need to be addressed in the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.